148 related articles for article (PubMed ID: 34941036)
1. Clinical insights into hematologic malignancies and comparative analysis of molecular signatures of acute myeloid leukemia in different ethnicities using an artificial intelligence offering.
Snowdon JL; Weeraratne D; Huang H; Brotman D; Xue S; Willis VC; Lee YK; Jeon K; Zang DY; Kim HJ; Kim HY; Han B; Kim M
Medicine (Baltimore); 2021 Dec; 100(51):e27969. PubMed ID: 34941036
[TBL] [Abstract][Full Text] [Related]
2. Clinical evaluation of panel testing by next-generation sequencing (NGS) for gene mutations in myeloid neoplasms.
Au CH; Wa A; Ho DN; Chan TL; Ma ES
Diagn Pathol; 2016 Jan; 11():11. PubMed ID: 26796102
[TBL] [Abstract][Full Text] [Related]
3. [Detection of FLT3 gene mutation in hematologic malignancies and its clinical significance].
Liu H; Yu H; Jia HY; Zhang W; Guo CJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Aug; 15(4):709-13. PubMed ID: 17708788
[TBL] [Abstract][Full Text] [Related]
4. Analytical validation and performance characteristics of a 48-gene next-generation sequencing panel for detecting potentially actionable genomic alterations in myeloid neoplasms.
Rosenthal SH; Gerasimova A; Ma C; Li HR; Grupe A; Chong H; Acab A; Smolgovsky A; Owen R; Elzinga C; Chen R; Sugganth D; Freitas T; Graham J; Champion K; Bhattacharya A; Racke F; Lacbawan F
PLoS One; 2021; 16(4):e0243683. PubMed ID: 33909614
[TBL] [Abstract][Full Text] [Related]
5. FMS-like tyrosine kinase 3 internal tandem duplication and the patterns of its gene sequence in 207 Chinese patients with de novo acute myeloid leukemia.
Zhong L; Jia YQ; Meng WT; Ni X
Arch Pathol Lab Med; 2012 Jan; 136(1):84-9. PubMed ID: 22208491
[TBL] [Abstract][Full Text] [Related]
6. Genetic alterations in Thai adult patients with acute myeloid leukemia and myelodysplastic syndrome-excess blasts detected by next-generation sequencing technique.
Owattanapanich W; Herzig J; Jahn N; Panina E; Ruchutrakool T; Kungwankiattichai S; Issaragrisil S; Döhner H; Döhner K
Ann Hematol; 2021 Aug; 100(8):1983-1993. PubMed ID: 33839881
[TBL] [Abstract][Full Text] [Related]
7. FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development.
Kiyoi H; Kawashima N; Ishikawa Y
Cancer Sci; 2020 Feb; 111(2):312-322. PubMed ID: 31821677
[TBL] [Abstract][Full Text] [Related]
8. Comparative analysis of target gene exon sequencing by cognitive technology using a next generation sequencing platform in patients with lung cancer.
Chen Y; Yan W; Xie Z; Guo W; Lu D; Lv Z; Zhang X
Mol Clin Oncol; 2021 Feb; 14(2):36. PubMed ID: 33414916
[TBL] [Abstract][Full Text] [Related]
9. Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome.
Kayser S; Schlenk RF; Londono MC; Breitenbuecher F; Wittke K; Du J; Groner S; Späth D; Krauter J; Ganser A; Döhner H; Fischer T; Döhner K;
Blood; 2009 Sep; 114(12):2386-92. PubMed ID: 19602710
[TBL] [Abstract][Full Text] [Related]
10. The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation-positive relapsed/refractory acute myeloid leukemia.
Altman JK; Perl AE; Hill JE; Rosales M; Bahceci E; Levis MJ
Cancer Med; 2021 Feb; 10(3):797-805. PubMed ID: 33340276
[TBL] [Abstract][Full Text] [Related]
11. The prognosis predictive value of FMS-like tyrosine kinase 3-internal tandem duplications mutant allelic ratio (FLT3-ITD MR) in patients with acute myeloid leukemia detected by GeneScan.
Lyu M; Liao H; Shuai X; Jin Y; Su J; Zheng Q
Gene; 2020 Feb; 726():144195. PubMed ID: 31669649
[TBL] [Abstract][Full Text] [Related]
12. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
[TBL] [Abstract][Full Text] [Related]
13. Pattern and prognostic value of FLT3-ITD mutations in Chinese de novo adult acute myeloid leukemia.
Liu SB; Qiu QC; Bao XB; Ma X; Li HZ; Liu YJ; Chen SN; Song YH; Wu DP; Xue SL
Cancer Sci; 2018 Dec; 109(12):3981-3992. PubMed ID: 30320942
[TBL] [Abstract][Full Text] [Related]
14. [FLT3 Mutations in Acute Myeloid Leukemia].
Shoji T; Kida Y; Yamashita K; Ichiyama S
Rinsho Byori; 2017 Jan; 65(1):44-51. PubMed ID: 30695511
[TBL] [Abstract][Full Text] [Related]
15. Clinical Effect of Combined Mutations in DNMT3A, FLT3-ITD, and NPM1 Among Egyptian Acute Myeloid Leukemia Patients.
El Gammal MM; Ebid GT; Madney YM; Abo-Elazm OM; Kelany AK; Torra OS; Radich JP
Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):e281-e290. PubMed ID: 30926392
[TBL] [Abstract][Full Text] [Related]
16. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197
[TBL] [Abstract][Full Text] [Related]
17. Clinical implications of non-A-type NPM1 and FLT3 mutations in patients with normal karyotype acute myeloid leukemia.
Park BG; Chi HS; Park SJ; Min SK; Jang S; Park CJ; Kim DY; Lee JH; Lee JH; Lee KH
Acta Haematol; 2012; 127(2):63-71. PubMed ID: 22104247
[TBL] [Abstract][Full Text] [Related]
18. [Analysis of tyrosine kinases gene mutations in core binding factor related acute myeloid leukemia and its clinical significance].
Qiao M; Li WY; Sun AN; Chen SN; Liang JY; Ding ZX; Feng YF; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2011 Oct; 32(10):679-83. PubMed ID: 22339826
[TBL] [Abstract][Full Text] [Related]
19. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
Luskin MR; DeAngelo DJ
Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942
[TBL] [Abstract][Full Text] [Related]
20. Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.
Fischer T; Stone RM; Deangelo DJ; Galinsky I; Estey E; Lanza C; Fox E; Ehninger G; Feldman EJ; Schiller GJ; Klimek VM; Nimer SD; Gilliland DG; Dutreix C; Huntsman-Labed A; Virkus J; Giles FJ
J Clin Oncol; 2010 Oct; 28(28):4339-45. PubMed ID: 20733134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
